Literature DB >> 9425121

Inhibition of human cytosolic phospholipase A2 by human annexin V.

A G Buckland1, D C Wilton.   

Abstract

The ability of annexins, particularly annexin 1 (lipocortin 1), to inhibit phospholipase A2 (PLA2) is well known and a substrate depletion mechanism is now widely accepted as the explanation for most inhibitory studies. However, there are only a very limited number of reported studies involving annexins and the high-molecular-mass cytosolic PLA2 (cPLA2). In this study we have examined the effect of human recombinant annexin V, a potentially abundant cytosolic protein, on the ability of human recombinant cPLA2 to hydrolyse a variety of phospholipid substrates. The results show clearly that, under the conditions of our study, annexin V can inhibit cPLA2 activity by a mechanism of substrate depletion and that this inhibition is dependent on the nature of the phospholipids and the concentration of Ca2+ ions in the assay. The hydrolysis of 1-stearoyl 2-arachidonyl phosphatidylcholine by cPLA2 was not significantly affected by annexin V over a range of Ca2+ concentrations (1 microM-2.5 mM), a result that presumably reflects the zwitterionic nature of the phospholipid and the known inability of annexins to bind to such interfaces. In contrast, the hydrolysis of dioleoyl phosphatidylglycerol, which is an effective anionic phospholipid substrate for this enzyme, and more significantly that of 1-stearoyl 2-arachidonyl phosphatidic acid, were readily inhibited by annexin V, although these effects were Ca2+-dependent. The Ca2+ concentrations required for inhibition in the assay system in vitro are greater than those associated with Ca2+-stimulated events within the cell, suggesting that a role for annexin V in regulating cPLA2 activity might not involve a substrate depletion mechanism in vivo unless factors in addition to Ca2+ and phospholipids contribute to the binding of annexin V to cell membranes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9425121      PMCID: PMC1219053          DOI: 10.1042/bj3290369

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  29 in total

1.  Crystal and molecular structure of human annexin V after refinement. Implications for structure, membrane binding and ion channel formation of the annexin family of proteins.

Authors:  R Huber; R Berendes; A Burger; M Schneider; A Karshikov; H Luecke; J Römisch; E Paques
Journal:  J Mol Biol       Date:  1992-02-05       Impact factor: 5.469

2.  A continuous fluorescence displacement assay for the measurement of phospholipase A2 and other lipases that release long-chain fatty acids.

Authors:  D C Wilton
Journal:  Biochem J       Date:  1990-03-01       Impact factor: 3.857

3.  Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation.

Authors:  R J Flower; G J Blackwell
Journal:  Nature       Date:  1979-03-29       Impact factor: 49.962

4.  Binding of vascular anticoagulant alpha (VAC alpha) to planar phospholipid bilayers.

Authors:  H A Andree; C P Reutelingsperger; R Hauptmann; H C Hemker; W T Hermens; G M Willems
Journal:  J Biol Chem       Date:  1990-03-25       Impact factor: 5.157

5.  Anionic phospholipids stimulate an arachidonoyl-hydrolyzing phospholipase A2 from macrophages and reduce the calcium requirement for activity.

Authors:  C C Leslie; J Y Channon
Journal:  Biochim Biophys Acta       Date:  1990-08-06

6.  Expression of annexins as a function of cellular growth state.

Authors:  D D Schlaepfer; H T Haigler
Journal:  J Cell Biol       Date:  1990-07       Impact factor: 10.539

7.  Synthesis of a gene for rat liver fatty-acid-binding protein and its expression in Escherichia coli.

Authors:  A F Worrall; C Evans; D C Wilton
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

8.  Interactions of annexins with membrane phospholipids.

Authors:  P Meers; D Daleke; K Hong; D Papahadjopoulos
Journal:  Biochemistry       Date:  1991-03-19       Impact factor: 3.162

9.  Inhibition of protein kinase C by annexin V.

Authors:  D D Schlaepfer; J Jones; H T Haigler
Journal:  Biochemistry       Date:  1992-02-18       Impact factor: 3.162

10.  A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids.

Authors:  F Hirata; E Schiffmann; K Venkatasubramanian; D Salomon; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

View more
  5 in total

Review 1.  Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention.

Authors:  Edward A Dennis; Jian Cao; Yuan-Hao Hsu; Victoria Magrioti; George Kokotos
Journal:  Chem Rev       Date:  2011-09-12       Impact factor: 60.622

2.  Eicosanoid release is increased by membrane destabilization and CFTR inhibition in Calu-3 cells.

Authors:  Florence Borot; Diane-Lore Vieu; Grazyna Faure; Janine Fritsch; Julien Colas; Sandra Moriceau; Maryvonne Baudouin-Legros; Franck Brouillard; Jesus Ayala-Sanmartin; Lhousseine Touqui; Marc Chanson; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

3.  The calcium binding loops of the cytosolic phospholipase A2 C2 domain specify targeting to Golgi and ER in live cells.

Authors:  John H Evans; Stefan H Gerber; Diana Murray; Christina C Leslie
Journal:  Mol Biol Cell       Date:  2003-09-17       Impact factor: 4.138

4.  Isobaric Tagging-Based Quantification for Proteomic Analysis: A Comparative Study of Spared and Affected Muscles from mdx Mice at the Early Phase of Dystrophy.

Authors:  Cintia Yuri Matsumura; Bruno Menezes de Oliveira; Madeleine Durbeej; Maria Julia Marques
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

5.  Calcium-Dependent Cytosolic Phospholipase A2α as Key Factor in Calcification of Subdermally Implanted Aortic Valve Leaflets.

Authors:  Antonella Bonetti; Magali Contin; Federica Tonon; Maurizio Marchini; Fulvia Ortolani
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.